Clinicopathological significance and underlying molecular mechanism of downregulation of basonuclin 1 expression in ovarian carcinoma.

In this study, we aim to identify the clinical significance of basonuclin 1 () expression in ovarian carcinoma (OV) and to explore its latent mechanisms. Via integrating in-house tissue microarrays, gene chips, and RNA-sequencing data, we explored the expression and clinical value of in OV. Immunohistochemical staining was utilized to confirm the protein expression status of BNC1. A combined SMD of -2.339 (95% : -3.649 to -1.028, <0.001) identified that was downregulated based on 1346 samples, and the sROC (AUC = 0.93) showed a favorable discriminatory ability of in OV patients. We used univariate and multivariate Cox regulation to evaluate the prognostic role of for OV patients, and a combined hazard ratio of 0.717 (95% : 0.445-0.989, <0.001) revealed that was a protective factor for OV. Furthermore, the fraction of infiltrating naive B cells, memory B cells, and other immune cells showed statistical differences between the high- and low- expression groups through cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) algorithm. Enrichment analysis showed that may have a relationship with immune-related items in OV. By predicting the potential regulatory transcription factors (TFs) of , friend leukemia virus integration 1 () may be a potential upstream TF of . Corporately, a decreasing trend of may serve as a tumor suppressor and prognostic biomarker in OV patients. Moreover, may take part in immune-related pathways and influence the fraction of tumor-infiltrating immune cells.